Technical Analysis for MLYS - Mineralys Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 11.29 | 5.02% | 0.54 |
MLYS closed up 5.02 percent on Friday, April 19, 2024, on 57 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Stochastic Buy Signal | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Fell Below 200 DMA | Bearish | 5.02% | |
| Expansion Breakdown | Bearish Swing Setup | 5.02% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 4 hours ago |
| Rose Above 200 DMA | about 4 hours ago |
| Possible Inside Day | about 6 hours ago |
| Rose Above Lower Bollinger Band | about 10 hours ago |
| 200 DMA Resistance | about 10 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Hypertension Cardiovascular Disease Treatment Of Hypertension
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Hypertension Cardiovascular Disease Treatment Of Hypertension
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 17.7 |
| 52 Week Low | 5.86 |
| Average Volume | 181,106 |
| 200-Day Moving Average | 11.13 |
| 50-Day Moving Average | 13.66 |
| 20-Day Moving Average | 12.61 |
| 10-Day Moving Average | 12.38 |
| Average True Range | 0.69 |
| RSI (14) | 35.48 |
| ADX | 17.67 |
| +DI | 15.03 |
| -DI | 30.72 |
| Chandelier Exit (Long, 3 ATRs) | 11.78 |
| Chandelier Exit (Short, 3 ATRs) | 12.45 |
| Upper Bollinger Bands | 13.86 |
| Lower Bollinger Band | 11.36 |
| Percent B (%b) | -0.03 |
| BandWidth | 19.85 |
| MACD Line | -0.44 |
| MACD Signal Line | -0.26 |
| MACD Histogram | -0.1817 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.37 | ||||
| Resistance 3 (R3) | 12.25 | 11.77 | 12.19 | ||
| Resistance 2 (R2) | 11.77 | 11.49 | 11.83 | 12.13 | |
| Resistance 1 (R1) | 11.53 | 11.33 | 11.65 | 11.65 | 12.07 |
| Pivot Point | 11.05 | 11.05 | 11.11 | 11.11 | 11.05 |
| Support 1 (S1) | 10.81 | 10.77 | 10.93 | 10.93 | 10.51 |
| Support 2 (S2) | 10.33 | 10.61 | 10.39 | 10.45 | |
| Support 3 (S3) | 10.09 | 10.33 | 10.39 | ||
| Support 4 (S4) | 10.21 |
